Trial Profile

A Phase 1, Open-Label, Single Dose Parallel-Group Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brensocatib (Primary)
Indications Bronchiectasis; Chronic obstructive pulmonary disease; COVID 2019 infections; Cystic fibrosis; Hidradenitis suppurativa; Rhinosinusitis
Focus Adverse reactions; Pharmacokinetics
Sponsors Insmed

22 May 2024 Results assessing the pharmacokinetics (PK), safety, and tolerability of brensocatib in subjects with varying degrees of renal impairment and healthy subjects, presented at the 120th International Conference of the American Thoracic Society.
20 May 2024 According to an Insmed media release, data from this study presented at the American Thoracic Society 2024 International Conference Plenary Session.
20 Feb 2023 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com